Zuclopenthixol
Structural formula | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | |||||||||||||||||||
Non-proprietary name | Zuclopenthixol | ||||||||||||||||||
other names |
|
||||||||||||||||||
Molecular formula | C 22 H 25 ClN 2 OS | ||||||||||||||||||
External identifiers / databases | |||||||||||||||||||
|
|||||||||||||||||||
Drug information | |||||||||||||||||||
ATC code | |||||||||||||||||||
Drug class | |||||||||||||||||||
properties | |||||||||||||||||||
Molar mass | 400.97 g · mol -1 | ||||||||||||||||||
safety instructions | |||||||||||||||||||
|
|||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Zuclopenthixol is a heterocyclic organic- chemical compound from the group of thioxanthenes . The drug is used to treat psychosis . Zuclopenthixol is a dopamine - and serotonin receptor - antagonist . Zuclopenthixol was first marketed as Clopixol in 1986 by Lundbeck as an effective component of a drug .
Clinical information
Approved areas of application
Zuclopenthixol is approved for the treatment of acute and chronic schizophrenia , mania , psychomotor agitation and aggressive behavior in the case of intellectual disabilities or dementia .
unwanted effects
The following undesirable effects are very common: accommodation disorders , urge to move, dry mouth, tiredness (up to 80% at the beginning of treatment), muscle stiffness , Parkinson's disease , torticollis, dizziness, sitting restlessness , tremors and throat syndrome .
Loss of appetite, eye cramps, nausea, depression, diarrhea, dystonia , vomiting , cardiac conduction disorders , photosensitivity , skin rash, headache, menstrual disorders , hives , increased reflexes or nausea occur frequently .
History
Zuclopenthixol was developed by the Danish company Lundbeck. It is the pure ( Z ) isomer (synonym: cis isomer) of the ( EZ ) isomer mixture (synonym: cis , trans isomer mixture) previously developed by Lundbeck, Clopenthixol , which was first marketed in 1986. Lundbeck licensed clopenthixol to Bayer for Germany . In 2000 Bayer withdrew Clopenthixol (a mixture of substances) from the market and replaced it with Zuclopenthixol.
Trade names and dosage forms
The drug Zuclopenthixol is sold in three different salt and ester forms:
- Zuclopenthixoldecanoate: as an injection solution for intramuscular depot administration ,
- Zuclopenthixol acetate: as an injection solution for intramuscular acute treatment,
- Zuclopenthixoldihydrochloride as tablets and drops for oral use .
All three salt and ester forms are available in Germany, Austria and Switzerland, but are sold under different trade names: Ciatyl-Z in Germany ( Bayer ), Cisordinol in Austria (Lundbeck) and Clopixol in Switzerland (Lundbeck).
See also
Individual evidence
- ↑ harmonized classification for this substance . A labeling of zuclopenthixol in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), retrieved on June 24, 2020, is reproduced from a self-classification by the distributor . There is not yet a
- ↑ E. Coutinho, M. Fenton, S. Quraishi: Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2000; CD001164. PMID 10796607 .
- ^ RC Gibson, M. Fenton, ES Coutinho, C. Campbell: Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev. 2004; CD000525. PMID 15266432 .
- ↑ A. Kumar, D. Strech: Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev. 2005; CD005474. PMID 16235403 .
- ↑ MG Izmeth, SY Khan, DI Kumarajeewa et al .: Zuclopenthixol decanoate in the management of behavioral disorders in mentally handicapped patients. In: Pharmatherapeutica. 5, 1988, pp. 217-227. PMID 2902642 .